Phase IB/II study to evaluate safety and preliminary efficacy of the WEE1 inhibitor Debio 0123 in combination with sacituzumab govitecan (SG) in triple-negative or hormone receptor–positive (HR+)/HER2-negative (HER2–) advanced breast cancer (ABC): The WIN-B study.

Authors: Timothy J. Robinson, Maria Gion, Isabel Blancas, Meritxell Aguiló, Juliana Carvalho Santos, Sandra Santasusagna, Michela Verbeni, Esteban Rodrigo Imedio, Luke Piggott, José Manuel Pérez García, Javier Cortes, Antonio Llombart-Cussac

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps3172

Source: Full article

---

Abstract

TPS3172